In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

BMS obtains rights to EntreMed's antiangiogenic compounds

Executive Summary

Bristol-Myers Squibb licensed exclusive worldwide rights to antiangiogenic uses of EntreMed's thalidomide (in Phase II for cancers, macular degeneration), thalidomide analogs, and the Angiostatin protein in a 5-yr. collaboration worth up to $76mm.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Alliance
    • Marketing-Licensing
    • Includes Equity
    • Includes Royalty or Profit Split Information

Related Companies